<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549260</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-002</org_study_id>
    <nct_id>NCT03549260</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose Finding Study to Evaluate the Efficacy and Safety of LIB003 in Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4
      weeks in subjects on stable statin and/or ezetimibe therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to assess the LDL-C lowering
      efficacy at Week 12 of various doses of LIB003 administered subcutaneously (SC) every 4 weeks
      (Q4W) in patients with hypercholesterolemia on stable diet and oral LDL-C-lowering drug
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 9, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled trial to evaluate LDL-C reduction with 3 different doses of LIB003 compared to placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind and Placebo-Controlled - Study drug administered by unmasked nurse who is not involved in any other aspects of the trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 12</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Change in serum LDL-C from baseline after 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>safety and tolerability will be based on the incidence and severity of treatment emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in apolipoprotein B (Apo B) at week 12</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Change in serum Apo B from baseline after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in lipoprotein (a) [Lp(a)] at week 12</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Change in serum Lp(a) from baseline after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in free PCSK9 at week 12</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Change in serum free PCSK9 from baseline after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti LIB003 antibodies (ADAs)</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Measurement of ADAs at baseline and various intervals</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>LDL Cholesterol</condition>
  <arm_group>
    <arm_group_label>LIB003 150 mg or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC LIB003 150 mg or placebo every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIB003 300 mg or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC LIB003 300 mg or placebo every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIB003 350 mg or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC LIB003 350 mg or placebo every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LIB003</intervention_name>
    <description>LIB003 or placebo</description>
    <arm_group_label>LIB003 150 mg or matching placebo</arm_group_label>
    <arm_group_label>LIB003 300 mg or matching placebo</arm_group_label>
    <arm_group_label>LIB003 350 mg or matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older

          2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic
             cardiovascular disease (ASCVD) event or evidence of ASCVD or without ASCVD but at high
             risk for ASCVD based on AHA/ACC CVD risk calculator, or aged 40 years and older with
             diabetes and moderate- to high-intensity statin, or pre-treatment LDL-C 190 mg/dL or
             greater or heterozygous familial hypercholesterolemia (HeFH)

          3. Body mass index (BMI) between 18 and 40 kg/m2

        Exclusion Criteria:

          1. Females of childbearing potential not using or willing to use an effective form of
             contraception, or pregnant or breastfeeding, or who have a positive serum pregnancy
             test at screening

          2. Homozygous familial hypercholesterolemia

          3. LDL or plasma apheresis within 2 months; lomitapide or mipomersen within 12 months

          4. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or
             stroke within 3 months prior to enrollment

          5. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or
             stroke within 3 months prior to enrollment

          6. Newly diagnosed or poorly controlled (HbA1c &gt;9%) type 2 diabetes

          7. Uncontrolled hypertension

          8. Moderate to severe renal insufficiency

          9. Elevated liver function test at screening

         10. Uncontrolled cardiac arrhythmia or prolonged QT on EKG

         11. A history of prescription drug abuse, illicit drug use, or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Institute For Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low density lipoprotein cholesterol</keyword>
  <keyword>PCSK9</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03549260/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03549260/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

